Iktos Appoints New Scientific Advisory Board to Accelerate AI-Driven Drug Discovery

Iktos Strengthens AI-Driven Drug Discovery with New Scientific Advisory Board

Iktos, a French scale-up company specializing in artificial intelligence and robotic solutions for medicinal chemistry and drug design, has announced the appointment of a new Scientific Advisory Board. This strategic move aims to accelerate the development of novel therapies and enhance the company's AI-first drug discovery platform 1

1

Renowned Experts Join Forces

The newly appointed board comprises five world-renowned experts in various fields crucial to modern drug discovery:

1. Rafael Gomez-Bombarelli: MIT professor and pioneer in Generative AI
2. Thierry Masquelin: Creator of the Lilly Life Science Studio (L2S2) and former automation leader at Recursion Pharmaceuticals
3. Friedrich Rippmann: Former Director of Computational Chemistry and Biologics at Merck KGaA
4. Laurent Debussche: Former VP Oncology Research at Sanofi
5. Dominique Bridon: Executive chairman at Sybilla Therapeutics

Each member brings unique expertise in areas such as AI-driven molecular design, lab automation, computational chemistry, first-in-human drug development, and strategic pipeline management 2

2

Advancing AI-First Drug Discovery

Iktos is revolutionizing drug discovery by addressing inefficiencies in traditional processes. The company's approach integrates generative design, robotic synthesis, and biological testing into a unified platform. This innovative method aims to accelerate the identification and optimization of effective treatments, creating a differentiated path to faster, more reliable ways of delivering life-saving therapies to patients 2

2

Related Stories

Osmo Launches Scientific Advisory Board to Advance Precision Nutrition

Mount Sinai Launches AI-Powered Center for Small Molecule Drug Discovery

Nvidia-Backed Iambic Therapeutics Unveils AI Breakthrough in Drug Discovery

Takeda inks $1.7 billion Iambic deal to accelerate AI drug discovery for cancer treatments

Iktos' Technological Arsenal

The company offers its technology through two SaaS software platforms:

1. Makya™ for generative drug design
2. Spaya™ for retrosynthesis

Additionally, Iktos has developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery 2

2

Recent Developments and Future Prospects

In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation, with contribution from Omnes Capital. More recently, in July 2024, the company acquired Synsight, complementing its Chemistry AI platform with a groundbreaking biology platform for discovering new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI) 2

2

Yann Gaston-Mathé, co-founder and CEO of Iktos, expressed enthusiasm about the new Scientific Advisory Board, stating that their insights will undoubtedly strengthen Iktos's mission to drive innovation in AI-first drug discovery 2

2